This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
Robert Malenka filed a Form 144 notice to sell MPLT common stock. The filing covers a planned sale of 241 shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of 4338.00, to be sold on or about 02/11/2026 on NASDAQ.
The 241 shares were acquired on 01/23/2026 as restricted stock vesting under a registered plan, in exchange for services rendered. The notice also lists recent sales of MPLT common stock during the past three months, including 21,262 shares sold on 01/29/2026 for gross proceeds of 394469.63 and 7,039 shares sold on 02/02/2026 for 126835.04.
Robert Malenka has filed a Form 144 notice to sell 6,622 shares of MPLT common stock. The shares were acquired on 01/23/2026 through restricted stock vesting under a registered plan, as payment for services rendered.
The planned sale, with an aggregate market value of $119,962.83, is to be executed through Morgan Stanley Smith Barney LLC on or around 02/10/2026 on the NASDAQ exchange. MPLT had 45,373,033 common shares outstanding at the time listed. Over the prior three months, Malenka reported several MPLT common stock sales totaling tens of thousands of shares and several hundred thousand dollars in gross proceeds.
MapLight Therapeutics executive Jonathan Gillis received new equity awards in the form of stock options and restricted stock units (RSUs). On February 5, 2026, he was granted 24,455 employee stock options to buy voting common stock and 6,020 RSUs of voting common stock.
The RSUs vest over time, with one-quarter vesting on January 1, 2027 and the remainder vesting in equal installments each April 1, July 1, October 1, and January 1 thereafter, subject to continued service. The options vest with one-quarter on February 5, 2027 and the rest in equal monthly installments, also contingent on continued service.
MapLight Therapeutics Chief Financial Officer Vishwas Setia reported new equity awards. On February 5, 2026, he acquired 7,730 shares of voting common stock at $0, described as a restricted stock unit (RSU) award. One quarter of these RSUs will vest on January 1, 2027, with the remainder vesting in equal installments on each April 1, July 1, October 1 and January 1 thereafter, contingent on continued service.
Setia was also granted an employee stock option for 31,395 shares of voting common stock at an exercise price of $15.7 per share, expiring on February 4, 2036. One quarter of the option will vest on February 5, 2027, with the balance vesting monthly in equal installments, also subject to continued service. Following these awards, he directly holds 395,549 shares of voting common stock and 31,395 stock options.
MapLight Therapeutics Chief Scientific Officer receives new equity awards. On February 5, 2026, Lillie James Woodruff was granted 7,730 restricted stock units of voting common stock and an option to purchase 31,395 shares at an exercise price of $15.7 per share.
The RSUs vest 25% on January 1, 2027, with the remainder vesting in equal quarterly installments, subject to continued service. The stock option vests 25% on February 5, 2027, with the balance vesting in equal monthly installments thereafter. Following the RSU grant, Woodruff beneficially owns 298,862 shares of voting common stock and 31,395 stock options, all held directly.
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported equity awards of 6,020 restricted stock units and 24,455 employee stock options dated February 5, 2026. The RSUs vest 25% on January 1, 2027, with the remaining 75% vesting in equal quarterly installments, subject to continued service.
The options have a $15.70 exercise price and begin vesting with 25% on February 5, 2027, then monthly vesting for the remaining shares. Following the RSU grant, Kreitzer directly holds 259,928 shares of voting common stock, and 24,455 options after the option grant.
MapLight Therapeutics, Inc. reported that its General Counsel, Kristopher Hanson, received new equity awards on February 5, 2026. He acquired 7,730 shares of voting common stock through a restricted stock unit grant at a stated price of $0, bringing his directly held total to 191,582 shares.
He was also granted an employee stock option for 31,395 shares at an exercise price of $15.7 per share. One quarter of the RSUs vest on January 1, 2027, and the remainder in equal quarterly installments, while one quarter of the option vests on February 5, 2027, with the balance vesting monthly thereafter, all contingent on continued service.
MapLight Therapeutics Chief Medical Officer Erin Pennock Foff reported new equity awards in the company’s voting common stock. She received 13,360 restricted stock units at a price of $0, which begin vesting on January 1, 2027 and then quarterly in equal installments, subject to continued service.
She was also granted an employee stock option for 54,240 shares at an exercise price of $15.7 per share. One quarter of these option shares vest on February 5, 2027, with the remainder vesting monthly thereafter, again contingent on ongoing service. Following these grants, she directly beneficially owns 403,835 shares of voting common stock and 54,240 options.
MapLight Therapeutics reported that Chief Executive Officer and director Christopher A. Kroeger received new equity awards. On February 5, 2026, he was granted 23,145 restricted stock units, each representing one share of voting common stock, at a price of $0. After this grant, he directly beneficially owned 1,649,751 shares of voting common stock.
On the same date, Kroeger also received an option to buy 93,955 shares of voting common stock at an exercise price of $15.70 per share, with vesting beginning in 2027. In addition, 101,190 shares of voting common stock are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse serve as co‑trustees with voting and dispositive power.
MapLight Therapeutics director Robert C. Malenka reported small open-market sales of voting common stock mainly to cover taxes on vested restricted stock units. On February 2, 2026, he sold 7,039 shares at a weighted average price of $18.02, and on February 3, 2026, he sold 1 share at $18.00.
After these sales, he beneficially owns 358,233 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he has voting and dispositive power. The remaining securities he holds are still subject to a 180-day IPO lock-up following the final prospectus dated October 26, 2025.